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Abstract
The steady-state concentration and thus the biological effects of NO are critically determined not only by its rate of
formation, but also by its rate of decomposition. Bioreactivity of NO at physiological concentrations may differ substantially
from that suggested by in vitro experiments. The charge neutrality and its high diffusion capacity are hallmarks that
characterize NO bioactivity. Reactive oxygen derived species are major determinants of NO breakdown. Biotransformation
of NO and its related N-oxides occurs via different metabolic routes within the body. S-Nitrosothiols formed upon reaction
of NO with redox-activated thiols represent an active storage pool for NO. The major oxidative metabolites represent nitrite
and nitrate, the ratio of both is determined by the microenvironmental redox conditions. In humans, circulating nitrite
represents an attractive estimate of regional endothelial NO formation, whereas nitrate, with some caution, appears useful in
estimating overall nitrogen/NO turnover. Within the near future, more specific biochemical tools for diagnosis of reduced
NO bioactivity will become available. Increasing knowledge on the complex metabolism of NO in vivo will lead to the
development of new therapeutic strategies to enhance bioactivity of NO via modulation of its metabolism. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
The steady-state concentration of nitric oxide
(NO) is determined by its rate of formation and its
rate of decomposition. A proper knowledge of the
metabolism of NO is requisite for our correct under-
standing and evaluation of its biological e¡ects, and
also for the development of reliable analytical meth-
ods to assess the production of NO in biological
systems. The metabolic pathway of NO in the intact
organism depends strongly on its site of administra-
tion and on its site of formation. In this paper, ex-
perimental and clinical data on the most relevant
metabolic pathways of endogenously formed NO
and on the biotransformation of exogenously applied
NO and its related N-oxides (NOx) will be reviewed
with particular emphasis on its metabolic routes in
the human body (see Fig. 1). The chemistry of NO
oxidation will be summarized as far as it appears
necessary for the understanding of NO metabolism
in organisms, for detailed chemical analysis of this
issue, the reader is referred to the reviews of Cooper
and Hughes in this volume.
2. General considerations on the physicochemical
properties of NO and related N-oxides
Nitrogen is unique among the elements in forming
no fewer than seven molecular oxides, three of which
are paramagnetic, and all of which are thermody-
namically unstable with respect to decomposition
into N2 and O2 [1]. NO is a colorless gas that is
sparingly soluble in water (6 2 mmol under stand-
ardized temperature, pressure, dryness (STPD) con-
ditions). The paramagnetic NO molecule contains
and odd number of electrons, which explains its
high reactivity and radical nature. Aside from its
reaction with O2, NO principally may react by elec-
tron gain to form the nitroxyl anion NO3, and by
electron loss to form NO, the nitrosonium ion [2].
The mode and rate of NO degradation may vary
considerably in the gaseous and in the aqueous phase
(see review by Hughes, this issue). The major break-
down product of NO in aqueous solutions is nitrite.
Kinetics of autoxidation of NO in aqueous solution
are dependent on the concentration of NO [3]. Con-
sequently, half-life is not a constant value and is in-
versely proportional to the concentration of NO, so
the half-life becomes much longer as nitric oxide be-
comes more dilute. At physiological concentrations
of NO (1 WM to 10 nM), the half-life of NO due to
the reaction with oxygen has been calculated to
range from 9 to 900 min [4]. In aqueous solution,
increasing partial oxygen pressure from 150 to 700
mmHg reduces half-life of a given amount of NO
from 6.2 to 3.8 s [5].
In biological systems, the mode and rate of NO
metabolism is dependent on its own concentration,
its di¡usibility, and the surrounding concentration of
other bioreactants. Di¡usion is essential for under-
standing the ability of NO to act as local modulator
and its major determinant of biological life time [4,6].
The charge neutrality of NO presumably facilitates
its free di¡usibility in aqueous solutions and across
cell membranes. Di¡usion constant of NO in aque-
ous solution amounts to 3300 Wm2 s31 at 37‡C,
which is 1.4-fold larger than the di¡usion coe⁄cient
of oxygen. The capacity of NO to di¡use long dis-
tances in tissues has been demonstrated using aque-
ous standards of authentic NO infused into coronary
circulation of saline perfused hearts. In the absence
of hemoglobin, NO rapidly di¡uses along the vascu-
lature and reaches vascular smooth muscle cells and
mitochondria of cardiomyocytes in su⁄ciently bioac-
tive amounts to a¡ect coronary blood £ow and left
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ventricular function [7,8]. Within the myocardial tis-
sue, endothelial NO is avidly bound to myoglobin,
resulting in steady-state concentration of 0.1^0.3 WM,
which exerts inhibitory e¡ects on cytochrome oxidase
and the electron transfer of the respiratory chain in
the mitochondria [9]. Thus, in agreement with its
function as a paracrine mediator, NO can travel sig-
ni¢cant distances to reach target cells neighboring
the NO generating cell with little consumption or
direct reaction. Along this migration, in particular
at higher concentration, NO can interact with molec-
ular oxygen, thiols, and reduced hemoproteins. The
extent of either of these reactions largely depends on
the microenvironmental conditions under which NO
is released, most important, the concentration of oth-
er bioreactants [10], and this readily explains the
large variation in previously reported half-lives of
EDRF and NO (seconds to minutes) using di¡erent
bioassays and analytical techniques [11^13]. More
recently, it has been demonstrated that the reaction
of NO with O2 within the hydrophobic regions of
membranes is approximately 300 times more rapid
than in the surrounding aqueous medium [14]. That
implies that biological membranes and other hydro-
phobic tissue compartments are important sites for
disappearance of NO along its travelling from the
generating to the target cell.
Aside from molecular oxygen, several reactive oxy-
gen derived species (ROS), such as superoxide anion
(O32 ), hydrogen peroxide (H2O2) and hydroxyl radi-
cal (HOc) (for review see [15]) were suggested to be
involved in the breakdown of NO. The di¡erent ki-
netics of the reaction of NO with these oxygen-de-
rived radicals and their varying concentration in dif-
ferent cells and organs may account for the slight
inconsistency of the reported data on in vivo degra-
dation of NO. It has been shown that all three com-
pounds are produced by cells from mammalian spe-
cies, especially from the endothelial cells and
macrophages, both of which also capable of synthe-
sizing NO. Interestingly, it has been shown that pu-
ri¢ed constitutive, endothelial NO-synthase (ecNOS)
forms simultaneously NO and O32 , the ratio of both
depending on the concentration of the ecNOS sub-
strate L-arginine and the redox conditions of cofac-
tors [16]. NO reacts with O32 to form peroxynitrite
(ONOO3) at an almost near-di¡usion-limited rate of
6.7U109 M31 s31. Formation of peroxynitrite will
only occur where the appearance rate of NO and
superoxide formation are equal [17]. Peroxynitrite is
stable in alkaline solutions (pKa = 6.6), and decays
rapidly once protonated [4,18^20]. Di¡erent, and
not entirely clari¢ed, mechanisms have been dis-
cussed in the decomposition of peroxynitrous acid
[20^22]. It may decompose to hydroxyl radical and
nitrogen dioxide, both radicals held together in a
solvent cage. This cage mechanism may slow down
the decomposition process. Alternatively, an acti-
vated isomer of peroxynitrous acid (HOONOc) may
be formed. Under in vivo conditions, peroxynitrite
may react with the ubiquitous CO2 forming an un-
stable nitrosoperoxycarbonate anion adduct [23]. Ni-
trate is the major breakdown product of NO in the
presence of su⁄cient amounts of O32 . Superoxide
dismutase (SOD) in cultured endothelial cells has
been shown to protect NO via reducing it to the
nitroxyl anion NO3 aside from dismutation of super-
oxide anions [24]. Thus the half-life of NO and the
ratio of the ¢nal NO metabolites in aqueous solu-
tions, namely nitrite and nitrate, will depend on such
surrounding conditions as the type and amount of
oxygen-derived radicals, the pO2, the pH, the con-
centration of transition metals, thiols. These param-
eters must be taken into account when planing in
vitro experiments on isolated organs, vessels, cells
and enzymes to study the biological e¡ects of NO
and when estimating NO synthesis via its oxidative
products nitrite and nitrate.
3. Estimates of NO biotransformation in mammalian
species
Monitoring of 15N-labeled nitrogen excretion in
urine and feces has been used to examine the bio-
transformation of NO and related N-oxides. Yoshida
and co-workers studied the metabolic pathways of
both inhaled 15NO (108 ppm) and combined 15NO
blood injections in male Wistar rats [25]. After ex-
posure, the 15N was found in high levels in the blood,
serum, red blood cells and urine of the rats, and at
low levels in the trachea, lung, liver, muscle and kid-
ney. These studies demonstrated that: (1) both in-
haled and injected NO rapidly enters circulating
red blood cells to become oxidized and subsequently
excreted in urine [25]; and (2) neither NO nor its
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metabolites are stored in relevant amounts in various
tissues for longer periods (see Fig. 1). In follow-up
balance studies, rats were given intraperitoneal injec-
tions of either 15N-labeled NO, nitrite and nitrate, or
were exposed to inhaled NO [26]. Up to 93% of the
inhaled 15N was recovered as nitrate in urine within
48 h. Comparable observations were made following
intraperitoneal injection of 15NO32 and
15NO33 . How-
ever, the 15N-urea content in urine was much lower
in the nitrate than in the nitrite injection, suggesting
that a fraction of injected nitrite entered the urea
cycle (see Fig. 1). Thus the major pathway for exo-
genously administered NO, at least in rats, involved
stepwise oxidation to nitrite and nitrate, the latter
being the major metabolite in urine [26].
Tannenbaum and his group later determined that
mammalian species are capable of endogenously pro-
ducing nitrate, the ¢nal urinary metabolite of NO.
Using orally administered, labeled (15NH3)-nitrogen,
they demonstrated that, in normal or germ-free rats,
the net excretion of nitrate is greater than the
amount ingested [27^29]. This disproved the notion
that the excess nitrate was derived exclusively from
bacterial synthesis of nitrate in the intestine. More-
over, almost 50% of the administered 15NH3 was
converted to nitrate and then excreted in the urine.
The remaining 50% of nitrogen nitrate was derived
from an as yet unidenti¢ed source. Using 15NH3 in
rats treated with endotoxin, it was demonstrated that
mammalian nitrate synthesis could be increased sev-
eral fold. At that time, it was concluded that the
pathway of nitrate biosynthesis may result from ox-
idation of reduced nitrogen compounds by oxygen
radicals generated by an activated reticuloendothelial
system [29]. Retrospectively, the increase in net ni-
trate synthesis in that study is now known with cer-
tainty to derive from inducible NO-synthase (iNOS).
As early as in 1916, it was proposed that body
tissues are able to produce nitrate [30]. The reported
estimates of net nitrate synthesis vary greatly, and
range from 150 to 1000 Wmol day31 [31^34]. Green
et al. observed that the amount of excreted nitrate in
urine was four times the amount ingested under con-
ditions of low nitrate ingestion. Balance studies with
15NO33 showed that endogenous biosynthesis of ni-
trate was the source of excess nitrate in urine. Anal-
ysis of 15NO33 data also revealed that half of all in-
gested nitrate was recovered as urinary nitrate [31].
However, nitrate balance studies using either labeled
or unlabeled nitrogen [31,33^36] provide only a
crude index for biotransformation and calculation
of endogenous L-arginine-derived NO synthesis in
humans, since the excretion of nitrite and nitrate,
the ¢nal metabolites of NO, is in£uenced by a num-
ber of other independent factors. These include: (1)
washout of previously ingested nitrate [33]; (2) in-
haled intake of atmospheric NOx compounds [33] ;
(3) metabolism by the urea cycle [26] ; (4) oxidation
of NOx in the gut; (5) absorption and reverse di¡u-
sion at di¡erent sites of the gastrointestinal tract (see
below); and (6) endogenous reduction of nitrate and
nitrite by mammalian tissue (see review by Zweier,
Fig. 1. Biotransformation of NO and its related N-oxides in mammalian organisms.
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[37]). Because of these factors, which all a¡ect nitro-
gen balance studies, urinary nitrate is a seemingly
unreliable parameter for studying the synthesis and
biotransformation of NO in humans.
Recently, this limitation has been in part overcome
by the administration of L-arginine with a 15N-gua-
nidino group to normal volunteers [38,39]. In these
studies, it has been shown, that nitrogen from L-ar-
ginine is incorporated into urinary nitrate in human
subjects [39]. Using 15N-labeled L-arginine, Castillo
et al. [38] demonstrated that 0.34% of all dietary
arginine was used for NO synthesis within the
splanchnic region and that 16% of the daily endoge-
nous nitrate output was formed from dietary argi-
nine taken up during its ¢rst pass within the splanch-
nic region. Finally, the fact that intravenous
infusions of [15N2]arginine labeled urinary NO33 to
a lower extent than intragastric administration of
the tracer indicates that there is signi¢cant compart-
mentation of arginine metabolism within the whole
body [38].
4. Metabolism of NO and related N-oxides in the
respiratory tract
NO is known to react with oxygen in air to form
the brown fumes of nitrogen dioxide (NO2). In the
gaseous phase, NO and NO2 are the major N-oxides
that humans are exposed to. NO and NO2 are in
dynamic equilibrium, so NO can be oxidized to
NO2, the rate of which depends on the presence of
dispersed particles, molecular oxygen, ozone (O3)
and solar radiation intensity. NO2 can also undergo
photodecomposition to form NO and O3. In gaseous
phases, the reaction velocity of NO and O2 is two
orders of magnitude lower as compared to that from
aqueous solutions. At room temperature, NO com-
bines with molecular oxygen to form NO2 at a rate
that is dependent on the oxygen concentration and
the square of the NO concentration [40]. Therefore,
oxidation is extremely slow at very low concentra-
tions. This ¢nding has important consequences for
the pathophysiological and pharmacological rele-
vance of NO in the respiratory tract.
In urban atmospheres, the NOx concentration rises
up to 0.1 ppm [41,42], mainly due to automobile
exhaust and industrial fumes. NO, rather than
NO2, is the major component of photochemical
smog. Thus, the inhabitants of industrialized nations
are exposed to daily concentrations of NO that
might achieve biological e¡ects if dissolved in aque-
ous solution. Puri¢ed water exposed to an urban
atmosphere for 1 h accumulates nitrite to a concen-
tration up to 300 nM [13]. The average human at-
mospheric exposure to gaseous nitrogen compounds
would amount to 1.5^3.1 mg nitrate day31, if all
inhaled N-oxides were converted within the body to
nitrate and then excreted in urine [33]. To under-
stand what happens to these N-oxides after inhala-
tion and entering the living body, it is important to
know how they normally react in aqueous solutions
and that the mode of reaction is oxygen dependent.
In the absence of oxygen, NO2 dimerizes to N2O4,
which then hydrolyzes to yield nitrite and nitrate. In
the presence of oxygen, NO2 readily combines with
an excess of NO to form N2O3, which then hydro-
lyzes to nitrite [12,43].
Three major physicochemical features of NO de-
termine its crucial role in the respiratory tract and
pulmonary circulation, which has led to the develop-
ment of new diagnostic and therapeutic approaches:
(1) the extremely slow reaction kinetics of NO and
oxygen in gaseous phases at low concentrations of
NO [40]; (2) its high di¡usion capacity; and (3) the
extremely rapid reaction of NO with HbO2. All of
these factors led to rapid removal of NO from the
lungs without systemic side e¡ects. Thus mainte-
nance and uptake of NO in the airways and in
lung tissue is mainly dictated by the binding of NO
to intravascular hemoglobin. Recent data suggest
that systemic side e¡ects of inhaled NO may occur
with higher doses of NO, such as inhibition of pla-
telet function and reduction of left ventricular per-
formance [44,45]. S-Nitrosoalbumin (SNO-Alb) and
S-nitrosohemoglobin (SNO-Hb) may represent pos-
sible candidates to mediate systemic biological e¡ects
of inhaled NO, which cannot be explained by NO
itself, because of its short half-life in circulating
blood [46].
NO has been introduced as a gas to test alveolar-
capillary di¡usion instead of CO, and is now com-
monly used [47,48]. NO inhalation (40^80 ppm) has
been suggested as a method of selectively reducing
pulmonary vascular and bronchial resistance without
reducing systemic blood pressure [49]. It has also
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been suggested that NO plays a role in the pulmo-
nary circulation and in the normal oxygenation of
blood through regulation of ventilation/perfusion
matching [50]. More recently, the presence of endo-
genously formed NO in the exhaled air of humans
(0.08 ppb), anesthetized rabbits (15 ppb) and guinea
pigs has been demonstrated [51^54], suggesting that
both exogenously applied and endogenously formed
NO may modulate bronchial resistance. Exhaled NO
derived from L-arginine may be formed either by
macrophages present in airway lining £uid, by the
pulmonary endothelium itself, or by epithelial cells
in the terminal and respiratory bronchioles or in
the nasopharynx [51,52,55].
5. Metabolism of NO and related N-oxides in the
systemic circulation
The metabolism of inhaled, injected and endoge-
nously formed NO, NO2, N2O3, NO32 and NO
3
3 in
blood depends on di¡usion, convection, the distribu-
tion coe⁄cient and chemical reactions within the dif-
ferent compartments of human blood (see Fig. 2 and
Table 1). Although NO may di¡use in tissue across
distances of more than 100 Wm, the hemoglobin of
circulating erythrocytes represent a signi¢cant sink
for NO [56]. Thus, red blood cells provide a drain
of NO that creates a sharp di¡usion gradient leading
to the vasculature. A red blood cell can reduce the
internal concentration of NO in an NO-producing
cell because oxyhemoglobin will greatly reduce the
re-entry of NO into the cell. Endothelium can
make 10- to 40-fold more NO than needed to acti-
vate guanylate cyclase, as measured by microelec-
trodes placed against isolated cells [57], but the
majority by the nitric oxide will be lost to the vas-
cular compartment. Even after nitric oxide has dif-
fused into the smooth muscle, it can rapidly di¡use
back along the di¡usion gradient to the red blood
cell [4]. Conductance of NO in blood was determined
to be 4.4 ml NO (STPD) min31 ml31 torr31 [47]. The
half-life of NO in blood has been estimated in the
range of 0.05^1.8 ms [11,58].
The uptake of gases such as O2, CO and NO by
erythrocytes involves: (1) di¡usion across the cellular
membrane; (2) intra-erythrocyteric di¡usion; and (3)
chemical combination with hemoglobin [59]. In vitro
combination of NO and free oxyhemoglobin is al-
most instantaneous [59,60]. The rate of this reaction
has been determined with a second-order rate con-
stant of 3.4U107 M31 s31 [61]. The rate constant for
NO uptake by human red blood cells was reported to
be 167 mM31 s31 [47,59]. Studies comparing shrunk-
en, discoid and spherical erythrocytes have demon-
strated that the orientation of membrane molecules
and the intracellular hemoglobin concentration are
critical determinants of the rate of NO uptake by
red blood cells [59]. In extension of these earlier ob-
servations, Liu and colleagues recently demonstrated,
that the reaction of NO with oxyhemoglobin within
the erythrocytes is limited by its di¡usion into the
cell [58] and that the hydrophobic micro-environ-
ment of the cellular membrane may represent an ad-
ditional sink for NO [14]. Thus, the rate of reaction
of NO with oxyhemoglobin within the erythrocytes is
up to 650 times slower compared to that with free
oxyhemoglobin [58]. When studying the reactions of
NO and its N-oxides with hemoglobin derivatives,
one must distinguish between hemoglobin (Hb), oxy-
hemoglobin (HbO2) and methemoglobin (MetHb),
all of which have a di¡erent a⁄nity for NO. In the
absence of oxygen, the a⁄nity of NO for hemoglobin
is about 1500 times higher than that of CO. The half-
time for dissociation of the ¢rst NO molecule from
Hb4(NO)4 at 19‡C is about 8 h at pH 9, and 3 h at
pH 6 [62]. NO combines with reduced hemoglobin 5^
20 times faster than oxygen [62]. The rate constants
for the combination of sheep hemoglobin with the
¢rst and fourth molecules of NO are 3U107 and
2.5U107 M31 s31, respectively [63]. Only under anaer-
obic conditions NO does combine with hemoglobin
to form nitrosyl-hemoglobin, whereas in the presence
of oxygen methemoglobin is the dominant product.
Oda et al. [64] were the ¢rst to identify very small
amounts of nitrosylhemoglobin in the blood of mice
after inhalation of 10 ppm NO for 1 h. The di⁄culty
in detecting nitrosylhemoglobin in vivo is due to the
fact that nitrosylhemoglobin in the presence of oxy-
gen and methemoglobin reductase is rapidly con-
verted to HbO2 via MetHb within the erythrocyte
[65]. The reaction of NO with oxyhemoglobin di¡ers
from its reaction with Hb and MetHb in that the
kinetics are even more rapid, and that the underlying
mechanism is a co-oxidation of NO and oxyhemo-
globin [66]. In partially deoxygenated solutions con-
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taining HbO2 and Hb exposed to NO, the propor-
tion of MetHb and nitrosylhemoglobin corresponded
closely to the initial ratio of [HBO2] to [Hb] [66].
This ¢nding has recently been con¢rmed: in venous
blood exposed to NO, more nitrosylhemoglobin and
less nitrate was detected as compared to arterialized
blood, in which more nitrate and less nitrosylhemo-
globin was measured [67]. Also, the reaction of NO
with the cysteine-L93 of the L-subunit forming S-ni-
trosohemoglobin is oxygen-dependent and facilitated
in the oxygenated status, whereas deoxygenation is
accompanied by an allosteric transition in SNO-Hb
that releases the NO group [46]. It has been sug-
gested that this conformation-associated changes in
the position of cysteine-L93-SNO brings local blood
£ow in line with oxygen requirements [68]. In vitro, it
has been shown that a small fraction of oxyhemoglo-
bin reacts with peroxynitrite, another oxidative inter-
mediate of NO metabolism [69]. The in vivo rele-
vance of this observation has yet to be established.
The nitrite anion is a causative factor of methemo-
globinemia. In plasma NO is oxidized almost com-
pletely to nitrite, where it remains stable for several
hours [13,70]. In contrast, nitrite is rapidly converted
to nitrate in whole blood. Oxidation of hemoglobin
by nitrite under aerobic conditions occurs via a slow
single-electron transfer from nitrite to the bound di-
oxygen of hemoglobin, and a rapid subsequent auto-
catalytic mechanism in which either a superoxide
anion, peroxide, nitrogen dioxide, a peroxynitrate
ion or a free methemoglobin radical is assumed to
be involved [65,71^74]. The in vivo relevance of these
mechanistic in vitro investigations has been con-
¢rmed recently: intratracheal administration of
13NO32 to rats or mice revealed that 70% of the
13N was converted to 13NO33 and 27% remained as
nitrite. The conversion site was within the erythro-
cyte, and the rate of conversion in rabbits was slower
than in mice [75]. After an intravenous injection of
sodium nitrite solution, the blood concentration of
nitrite in rabbits decreased rapidly in a ¢rst-order
manner [76]. When 5 WM NO32 is added to human
blood, it is completely converted to nitrate within
approximative 10 min [70]. The half-life of nitrite
in human blood amounts to 110 s (see Fig. 3). This
conversion is pH- and temperature-dependent, but is
not dependent on the amount of free hemoglobin
[13,70]. The above-mentioned lag period in the reac-
Fig. 2. Simpli¢ed scheme of possible metabolic pathways of NO in circulating blood. NO released from endothelial cells may reach
the erythrocytes to react with either oxyhemoglobin to form nitrate, or with hemoglobin to form nitrosylhemoglobin, or with the 93-
cysteine residue of the L-subunit to form S-nitrosohemoglobin. The ratio of these reactions is dependent on partial oxygen pressure.
In the aqueous phase of the plasma, NO may react with molecular oxygen to form nitrite, or with superoxide to form peroxynitrite.
The subsequent decomposition of peroxynitrite and thus the ratio of formed nitrite and nitrate depends on the surrounding condi-
tions. Alternatively, the nitrosonium moiety of NO may react with thiols in the presence of electron acceptors to form nitrosothiols.
The majority of the metabolic routes in plasma lead to the oxidative intermediate nitrite (shaded area).
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tion of NO32 and HbO2 is one of the prerequisites to
capture nitrite during blood sampling and to use ni-
trite levels as a reliable parameter for the assessment
of NO release by ecNOS from endothelial cells in
humans.
The metabolic pathways of NO and its N-oxides in
plasma di¡er somewhat from those in red blood cells
(see Fig. 2). When human plasma is exposed to NO
or NO2, a rapid loss of anti-oxidants, such as ascor-
bic acid, uric acid and most importantly protein thi-
ols, occurs [77]. The greater prevalence and reactivity
of thiols over other biological nucleophiles explain
the propensity for S-nitrosothiol (RSNO) formation.
NO does not react directly with thiols [78]. Thiols in
the presence of electron acceptors (redox-activated
thiols) react with the nitrosonium moiety of NO to
form RSNO which may represent a storage pool for
NO [79^82]. Human plasma contains low micromo-
lar concentrations of RSNO (see Table 1), the ma-
jority of which are accounted for by S-nitroso serum
albumin [83^85]. Cysteine is the sole thiol source
in proteins and also serves as the thiol residue of
glutathione. The level of total glutathione
(GSH+GSSG) amounts to about 20 WM, about
85% of which is in the form of GSH [86,87]. The
GSH status in plasma might a¡ect the metabolism
of NO. Thus, the major RSNO-compounds di¡er
with respect to their circulating concentration and
half-life following the rank order: SNO-Alb, S-nitro-
soglutathione (GSNO), S-nitrosocysteine (CysNO)
(see Table 1). This is of great signi¢cance for NO
metabolism and the biological e¡ects of endothelial
NO released into circulating blood at a constant rate
by ecNOS.
In the following, only the mechanisms and aspects
of RSNO decomposition will be discussed as far as
relevant to the understanding of NO metabolism.
For detailed analysis of the chemistry of thiols and
RSNO, reviews on this subject [88,89] and the review
by Gaston in this issue are referred. Biological ac-
tions of S-nitrosothiols may be associated with het-
erolytic as well as homolytic mechanisms of de-
composition, forming either NO, NOc, NO3.
Heterolytic pathways of RSNO decomposition ap-
pear to predominate over the homolytic release of
NO and account for many biological activities
[46,89]. Superoxide is involved in the metabolism of
the CysNO and GSNO. The substantially slower re-
action rates of superoxide with nitrosothiols relative
to the reaction rate with NO are consistent with the
contention that the transient formation of RSNO
stabilizes bioactive amounts of NO, thus enabling
these compounds to serve as carriers or bu¡ers of
NO [90]. The presence of trace transition metal
ions such as Cu2 and most importantly Cu1 [91],
which are present in most bu¡er systems and in cir-
Table 1
Synopsis of NO, N-oxides and their predominant bioreactants in circulating blood
Parameter Molecular weight
(g)
Concentrationa;b
(Wmol l31)
Half-lifea Reference
Nitric oxide NO 30 0.003^1.0 (P) 0.05^1 s (B) [4,11,70,83,97,128]
Nitrite NO32 46 0.1^0.5 (P) 110 s (B) [106]
Nitrate NO33 62 30^60 (P) 5^8 h (B) [34,128]
Peroxynitrite ONOO3 62 n.d.c n.d.c
Hemoglobin Hb 64 458 2.2U103 (B) [41,129]
Albumin Alb 69 000 500 (P) [83,129]
Glutathione Glu 307 20 (P) 25^45 min [86,89]
Cysteine Cys 121 10^30 (P) [88,89]
S-Nitrosoalbumin SNO-Alb 69 029 0.25^7.0 (P) 15^40 min [4,82,83,85,88]
S-Nitrosoglutathione GSNO 361 0.02^0.2 (P) 8 min [85,88]
S-Nitrosocysteine CysNO 160 0.2^0.3 (P) 6 1 min [88,93]
Nitrosylhemoglobin NO-Hb 64 488 0.5 (a)^0.9 (v) (B)(B) 6 1 min [46]
S-Nitrosohemoglobin SNO-Hb 64 487 0.3 (a)^0.003 (v) (B) 6 1 min [46,88]
aConcentration or half life of respective constituent in: (P), plasma; or (B), blood.
b(a), arterial, (v), venous.
cn.d., not determined or no precise literature data available
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culating blood (in human blood: 1 WM of soluble Cu
and about 15 WM of total Cu) stimulates the break-
down of S-nitrosothiols to NO and disul¢de. Thiyl
radicals are not formed as intermediates in this proc-
ess. Reducing agents, such as glutathione and ascor-
bate, can stimulate decomposition of S-nitrosothiols
by chemical reduction of contaminating transition
metal ions. Equilibrium constants of transnitrosation
reactions indicate that S-nitrosoglutathione forma-
tion is favored [92]. The transfer of NO from albu-
min to L-cysteine was directly measured in rabbit
plasma, indicating that in vivo an intensive NO ex-
change between high and low molecular weight thiol
pools may exist [93]. Thus, NO can be stabilized via
its intermediate SNO-Alb serving as reservoir for
highly reactive and short-lived low molecular weight
nitrosothiols (GSNO and CysNO), which readily can
pass cellular membranes and get intracellular access
to the NO target cell. The relevance of this concept
to the in vivo situation has yet to be established.
Con£icting with reports in vitro, the thiol N-acetyl-
cysteine does not modulate endothelium-derived re-
laxing factor (probably NO-mediated) responses at
least in the human forearm circulation [94]. Further-
more, the in vitro production of NO from RSNOs
does not always correlate with the extent of its vaso-
dilatory e¡ects [88]. Nevertheless, at least GSNO has
been proven to be a selective and potent inhibitor of
platelet activation in humans [95].
6. Circulating blood nitrite and nitrate as markers of
endogenous NO synthesis
In general, the NO detected at the luminal surface
of the endothelium may re£ect only a relative index
of total NO synthesized in the vascular endothelium
[96]. However, there is compelling experimental evi-
dence that the NO, and thus also its oxidative prod-
ucts nitrite and nitrate, detected at the luminal side
re£ects a constant proportion of total endothelial
NO synthesis [6,12,97]. Nitrite is the primary oxida-
tive product of NO derived from the conversion of L-
arginine to NO by the puri¢ed enzyme ecNOS [98].
Depending on the microenvironmental redox-condi-
tions it may be further oxidized to nitrate. The ra-
tionale to quantify endogenous NO formation via
the measurement by the sum of its N-oxides is prin-
cipally supported by the observation that circulating
NOx plasma levels are reduced by about 50% in ec-
NOS-knock-out mice as compared to control mice:
0.74 vs. 1.6 WM [99]. However, nitrite and nitrate
di¡er considerably in their half-life and distribution
volume, and, therefore, in their speci¢city in re£ect-
ing endothelial NO synthesis.
The serum concentration of nitrite might be af-
fected not only by the endothelial synthesis of NO
and its aforementioned oxidative pathways, but also
by the further metabolism of nitrite (see Fig. 2). Be-
cause of the short half-life of nitrite (see Fig. 3), the
simple measurement of plasma nitrite ex vivo with-
out preventing its rapid conversion to nitrate during
blood sampling is unlikely to be a reproducible and
accurate measure of endogenous NO synthesis. Be-
cause of its rapid turnover, plasma nitrite remains
almost constant [100], even following NO inhalation
[101]. Up to now, most studies have either failed to
Fig. 3. Half-life of nitrite in human blood. Fifty percent of ni-
trite added to human blood (0.1^10 WM) is rapidly converted
to nitrate within 110 s, whereas nitrate is stable in blood for
hours.
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detect NO/NO32 in the bloodstream, or they meas-
ured levels that were markedly inconsistent (the re-
ported ¢gures range from 3 nM to 20 WM)
[41,67,83,102]. In experimental settings, NO at the
luminal site of vascular endothelium has been re-
ported to be in the nanomolar to low micromolar
concentration range (0.3^1.3 WM) in di¡erent vascu-
lar beds [12,97,103,104]. Using 15N-labeled L-argi-
nine, it has been demonstrated in fasted young vol-
unteers that almost all of the circulating nitrite (90%)
is derived from the L-arginine^NO pathway [105].
Circulating nitrite can be derived from either NO
or alternatively from NO-related adducts, such as
peroxynitrite or RSNO. The reported data for serum
NO/NO32 in humans [103,105,106] are in line with
the concentration range of NO expected from exper-
imental data. At present, it cannot be distinguished
to which proportion the serum nitrite is derived from
NO or its related adducts (see Fig. 2). Nitrite may
arise from the reaction of endothelium-derived NO
with molecular oxygen or alternatively, in the pres-
ence of oxygen-derived radicals NO may be released
from the endothelium as peroxynitrite, which in turn
can react with circulating thiols to form nitrosothiols
or directly decompose to nitrite and oxygen [107].
Serum nitrosothiols are likely to be destabilized in
part during sampling procedure and consecutively
to form nitrite.
Recently, using highly sensitive HPLC techniques
for measurement of nitrite in combination with a
speci¢c sampling procedure preventing degradation
of blood nitrite [106], and standard plethysmo-
graphic techniques for quanti¢cation of forearm
blood £ow [108] we tested the speci¢city of serum
nitrite as an indicator of basal and stimulated NO
formation in human forearm vasculature in healthy
volunteers (see Fig. 4). Inhibition of ecNOS by L-
NMMA diminished endothelium-dependent £ow re-
sponse and nitrite concentration in the draining an-
tecubital vein under basal and acetylcholine-stimu-
lated conditions. In contrast, both parameters were
not a¡ected by the endothelium-independent vasodi-
lator papaverine. The notion that serum nitrite sen-
sitively re£ects changes in endothelial NO formation
Fig. 4. Speci¢city of nitrite as an index of endothelial NO synthesis in humans. Left-hand panels: upon infusion of acetylcholine into
the brachial artery forearm blood £ow (FBF) and serum nitrite in the antecubital vein increased signi¢cantly. Inhibition of endothelial
cNOS by L-NMMA (4 WM) signi¢cantly reduced both responses (closed triangles, control; open triangles, L-NMMA). Right-hand
panels : acetylcholine-induced (ACH) changes in nitrite were speci¢c, as the endothelium-independent vasodilator papaverine (PAP) in-
creased FBF to a comparable extent without a¡ecting nitrite (n = 12).
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is further strengthened by the observation that the
time course of acetylcholine-induced changes in ni-
trite closely paralleled the changes in £ow.
Uptake of endogenously formed NO into the red
blood cells with subsequent conversion to nitrate is
one of the possible metabolic pathways of NO in
humans [101]. Caution should be exercised when in-
creases in plasma nitrate as an index of NO forma-
tion are evaluated [100]. Sophisticated GC/MS tech-
niques using labeling of circulating nitrate pool with
either 15N or 18O isotopes may be helpful to assess
whole-body NO production via urine and plasma
analysis, although this approach does also not allow
to distinguish between vascular and non-vascular
sources of NO formation [105,109^111]. Further-
more, the serum level of nitrate appears to be an
unreliable measure of regional changes in ecNOS ac-
tivity as this parameter is in£uenced by a variety of
ecNOS-independent factors, such as the dietary ni-
trate intake, formation of saliva, bacterial synthesis
of nitrate within the bowl, denitrifying liver enzymes,
inhalation of atmospheric gaseous nitrogen com-
pounds, and the renal function [32,33,112^114]. Fur-
thermore, the natural abundance of nitrate with a
rather high background concentration in human
blood (micromolar range) would hamper exact meas-
urement of changes in endogenous NO formation by
ecNOS (nanomolar range).
The calculated half-life of circulating nitrate
amounts to 230 min [100] in dogs and up to 8 h in
humans [34]. This means that it would take about
20 h, that is ¢ve half-lives, to clear an elevated nitrate
level from plasma. This clearance rate is rather slow
because at least two renal mechanisms, ¢ltration and
reabsorption, will determine not only the plasma
half-life of nitrate, but also the amount of nitrate
appearing the urine. Because of the long half-life,
nitrate will accumulate not only in the venous blood,
but also in arterial blood, which prevents exact cal-
culation of the arterial^venous nitrate di¡erence, the
real measure of production by the whole body or a
speci¢c organ. Even measurement of the arterial^ve-
nous nitrate di¡erence across an organ may not re-
£ect the molar production rate of NO. The volume
distribution of nitrate in the conscious dog was
found to closely approximate the extracellular £uid
volume, not the plasma volume [100]. Therefore,
since the extracellular volume is about 5-fold that
of the plasma volume (21.5 to 4% of body weight,
respectively), the measurement of the concentration
of nitrate in plasma will grossly underestimate the
real production rate of NO. Measuring a plasma
concentration of 30 WM in a 70-kg man (plasma
volume about 3 l) re£ect an actual amount of 90
Wmol circulating nitrate. Taking into account the to-
tal extracellular volume, that is almost 15 l (21% of
70 kg), the total nitrate is 450 Wmol. Thus, in disease
states, e.g. heart failure, in which renal function and/
or extracellular volume is altered, the plasma half-life
of nitrate may even increase and thus the comparison
of plasma venous nitrate in normal patients and pa-
tients with heart failure may not re£ect an increased
production of NO/nitrate but rather an altered ex-
cretion of nitrate [100].
7. Metabolism of NO and related N-oxides in the
gastrointestinal tract
N-oxides in the intestine undergo a continuous
succession of changes, nitrate and nitrite being either
generated by nitri¢cation, destroyed by reductive me-
tabolism or chemical reaction, or transferred across
the intestinal wall either to or from the bloodstream.
Conditions in the lower gastrointestinal tract favor
bacterial denitri¢cation [113], whereas nitrite oxida-
tion predominates elsewhere in the gut [115,116].
Two-thirds of the nitrite entering the stomach origi-
nates in the saliva and slightly less than one-third
comes from nutrients [117]. In human saliva, the ni-
trate concentration was found to range from 200 to
600 WM, and nitrite ranges from 30 to 210 WM [118].
Bacterial reduction of nitrate to nitrite within the
human saliva depends on the pH, oxygen content
and character of bacterial £ora [42]. The dorsal sur-
face of the tongue harbors large numbers of nitrate-
reducing facultative anaerobic bacteria [119]. Some
of these bacteria can further utilize nitrite to NO
or even dinitrogen under anaerobic conditions (see
review by Watmough in this issue, [120]). The sali-
vary nitrite concentration is directly proportional to
the amount of nitrate ingested. Ingested nitrite can
be acidi¢ed within the stomach with subsequent di-
merization and dehydration to form N2O3, which
potentially can be converted to NO and NO2 [42].
Recently gastric NO concentration was reported to
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amount to 16 ppm, which could be increased almost
6-fold after oral administration of 2 mmol of potas-
sium nitrate [119]. Some of the ingested nitrite is
carried to the small intestine, where it is oxidized
to nitrate [42].
There is little or no uptake of nitrate from the
stomach. Uptake of nitrate from the gastrointestinal
lumen, which occurs primarily in the small intestine,
appears to be an active process. However, certain
quantities of nitrate can reach the lower intestinal
tract via the intestinal tube or by reverse di¡usion
from blood [34]. About 40^45% of ingested nitrate is
metabolized in the body rather than being excreted in
urine as nitrate, thus approximately half is metabo-
lized by mammalian processes and approximately
half by enteric bacteria, predominately by those of
the large bowel [112]. The ability to excrete nitrate
into the small intestine is unique to rats and does not
apply to humans ^ a fact that must be considered
when trying to extrapolate the results of studies on
NO/NO33 metabolism in rats to humans [42]. A sig-
ni¢cant increase of plasma nitrate in patients with
infective gastroenteritis has been described recently
[121].
8. Metabolism of NO and related N-oxides in urine
Due to the conversion of NO and nitrite to nitrate,
NO33 is the ¢nal metabolite of NO in human urine.
Nitrate is ¢ltered in the glomerula and reabsorbed in
the renal tubules. The concentration of nitrate in
urine is 250^2000 WM, whereas nitrite and NO usu-
ally are not detectable [118]. This fact is commonly
used for diagnosis of urinary tract infections, in
which bacterial contamination leads to NO synthesis
and later nitrate synthesis within the urinary tract.
Soluble and particulate fractions of human infected
urine contain an isoform of NO synthase which is an
endogenous source of urinary nitrite [122]. Whether
or not human urothel expresses constitutive and in-
ducible NO synthase remains unclear at present.
9. Daily production and breakdown of NO in
mammalian species
The steady-state concentration of NO is deter-
mined by the rate of formation and the rate of de-
composition. The rate of NO production by endo-
thelial cells in situ or in culture was measured at
around 4 pmol min31 mg protein31 [123,124]. This
would account for an NO production of 0.8 pmol
min31 mg31 endothelial cells, the mass of which is
1.5 kg in the whole body. Thus, the entire daily pro-
duction of endothelial NO by the ecNOS would
amount to 1728 Wmol person31, provided that these
in vitro data on endothelial NO formation can be
extrapolated to the in vivo situation and given the
fact that iNOS do not produce signi¢cant amounts
of NO under control conditions. These data perfectly
¢t with previous data, reporting a net synthesis of
nitrate, the stable end product of NO metabolism,
in the range from 1200 to 2200 Wmol person31
day31 [125]. Given a total of 450 Wmol nitrate (see
Section 6) in a 70-kg man and the reported nitrate
half-life of 8 h in humans [34,126], the rate of NO/
nitrate formation could be estimated with about 1050
Wmol 24 h31, which also is in line with the aforemen-
tioned calculations of daily NO production in hu-
mans.
However, a great deal of caution should be used
when estimating daily NO formation via its break-
down product nitrate. About 50% of circulating ni-
trate depends directly on oral nitrate intake [34,42].
The high intraindividual and interindividual variance
of circulating nitrate levels and urinary nitrate excre-
tion is illustrated by the fact that the daily nitrate
intake ranges from 75 to 150 mmol, while the output
exceeds the input by a factor of 2^60 [34]. Therefore,
human plasma and urine nitrate measurements
should be determined only after a low nitrate/nitrite
diet for at least 4 days, because substantial intraindi-
vidual variation of plasma nitrate became less after
the fourth day of diet [127]. Furthermore, it has been
suggested to measure urine samples taken before ni-
trate-rich meals re£ects more reliably endogenous
NO/nitrate formation as compared to samples taken
from the combined 24-h urine [114].
10. Conclusions
Biotransformation of NO and its related N-oxides
occurs via di¡erent metabolic routes within the body.
The major oxidative metabolites represent nitrite and
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nitrate, the ratio of both is determined by the micro-
environmental redox conditions. In humans circulat-
ing nitrite represents an attractive estimate of region-
al endothelial NO formation, whereas nitrate, with
some caution, appears useful in estimating overall
nitrogen/NO turnover. Within the near future,
more speci¢c biochemical tools for diagnosis of re-
duced NO bioactivity will become available. Increas-
ing knowledge on the complex metabolism of NO in
vivo will lead to develop new therapeutic strategies to
enhance bioactivity of NO via modulation of its me-
tabolism.
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